GoDx

GoDx, Inc. is a biotechnology company based in Madison, Wisconsin, specializing in the development of rapid, lab-grade molecular diagnostic platforms for point-of-care and environmental surveillance settings. The company has developed proprietary technologies such as the GoAMP nucleic acid amplification method and the GoDNA lateral flow detection system, which are designed to identify infectious pathogens and antimicrobial resistance (AMR) markers with high sensitivity. Their core product offerings include the GoGutDx platform for gastrointestinal pathogen identification, which is engineered to provide actionable results within approximately 30 minutes. By integrating portable, automated diagnostic hardware with advanced biochemical assays, GoDx aims to facilitate rapid, decentralized testing without the need for extensive laboratory infrastructure or professional interpretation, enhancing clinical diagnostic speed and accuracy.

These solutions address critical healthcare and public health challenges by enabling timely clinical decision-making, optimizing antimicrobial stewardship, and supporting environmental bio-surveillance efforts. By providing mobile and ruggedized diagnostic tools suitable for resource-limited or austere environments, the company supports applications ranging from pandemic readiness to infectious disease tracking in military and community healthcare settings. Supported by various federal and state research grants, including funding from the National Institutes of Health (NIH) and the Biomedical Advanced Research and Development Authority (BARDA), GoDx collaborates with academic and government institutions to advance medical countermeasures and expand the availability of rapid testing where it is needed most.